Monitoring long-term Efficacy of Fampridine in Gait-Impaired Patients with Multiple Sclerosis
Neurol 88:832-841, Filli, L.,et al, 2017
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Tizanidine for Spasticity
The Medical Letter 39:62, , 1997
Tizanidine Treatment of Spasticity Caused by Multiple Sclerosis:Results of a Double-Blinded, Placebo-Controlled Trial
Neurol 44:S34-S43, Smith,C.,et al, 1994
A Double-Blind, Placebo-Controlled Trial of Tizanidine in the Treatment of Spasticity Caused by Multiple Sclerosis
Neurol 44:S70-S78, Barnes,M.P.,et al, 1994
Treatment of Spasticity with Botulinum Toxin:A Double-Blind Study
Ann Neurol 28:512-515, Snow,B.J.,et al, 1990
Intrathecal Baclofen for Severe Spinal Spasticity
NEJM 320:1517-1521, 1553-15551989., Penn,R.D.,et al, 1989
Intrathecal Baclofen for Long-Term Treatment of Spasticity:A Multi-Centre Study
JNNP 52:933-939, Ochs,G.,et al, 1989
Continuous Intrathecal Baclofen for Severe Spasticity
Lancet 2:125-127, Penn,R.D.&Kroin,J.S., 1985
Baclofen for Spasticity in Multiple Sclerosis
Neurol 28:1094-1098, Feldman,R.G.,et al, 1978